Japanese pharma company Takeda Pharmaceuticals has acquired 100% of the common shares of American AI biotechnology company Nimbus Therapeutics’s fully owned subsidiary Nimbus Lakshmi and its Tyrosine kinase 2 (TYK2) (intracellular enzyme) program. The transaction was previously announced in December 2022.
Following the acquisition, Nimbus’ drug candidate NDI-034858 for psoriasis will be renamed to “TAK-279”. Takeda will be solely responsible for the development of the candidate and a Phase 3 clinical trial is slated to be conducted in 2023. The acquisition is expected to expand and strengthen Takeda’s late-stage pipeline.
As part of the transaction, Nimbus will receive USD 4 billion upfront and USD 1 billion each for two milestones–achieving net sales of USD 4 billion and USD 5 billion for products developed as part of the TAK-279 program.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.